Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy
Current treatment strategies and disease management programs for hyperlipidemia employ a range of li...
Cardiovascular disease is a leading cause of mortality around the globe. The atherosclerotic disease...
Five years after convening the expert panel, the 2013 ACC/AHA Guideline on the Treatment of Blood Ch...
Cardiovascular disease (CVD) remains the leading cause of death globally. A class of medications, kn...
AbstractThe American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Prac...
Guidelines for the reduction of cholesterol to prevent atherosclerotic vascular events were recently...
Since 2014, guidelines for the management of lipid disorders to reduce cardiovascular (CV) events ha...
The publication of the 2013 American College of Cardiology/American Heart Association guidelines on ...
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in deve...
Treatment guidelines have proliferated in cardiology, although most guideline recommendations are no...
the treatment of high blood cholesterol has had a strong impact due to the paradigm shift in its rec...
Importance: The 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol...
The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Gui...
Based on epidemiological, genetic, and clinical trial data, there is a consensus now that low-densit...
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the trea...
Current treatment strategies and disease management programs for hyperlipidemia employ a range of li...
Cardiovascular disease is a leading cause of mortality around the globe. The atherosclerotic disease...
Five years after convening the expert panel, the 2013 ACC/AHA Guideline on the Treatment of Blood Ch...
Cardiovascular disease (CVD) remains the leading cause of death globally. A class of medications, kn...
AbstractThe American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Prac...
Guidelines for the reduction of cholesterol to prevent atherosclerotic vascular events were recently...
Since 2014, guidelines for the management of lipid disorders to reduce cardiovascular (CV) events ha...
The publication of the 2013 American College of Cardiology/American Heart Association guidelines on ...
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in deve...
Treatment guidelines have proliferated in cardiology, although most guideline recommendations are no...
the treatment of high blood cholesterol has had a strong impact due to the paradigm shift in its rec...
Importance: The 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol...
The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Gui...
Based on epidemiological, genetic, and clinical trial data, there is a consensus now that low-densit...
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the trea...
Current treatment strategies and disease management programs for hyperlipidemia employ a range of li...
Cardiovascular disease is a leading cause of mortality around the globe. The atherosclerotic disease...
Five years after convening the expert panel, the 2013 ACC/AHA Guideline on the Treatment of Blood Ch...